Nonetheless, some observations have emerged from clinical immunotherapy studies, highlighting that even GBM IDH-wt is permissive for a continuous T-cell infiltration and activation and could be responsive to the action of immunotherapy [8,9,10,11]. This evidence concerns the gene IDH1 and glioblastoma.